Tech Company Financing Transactions

Unum Therapeutics Funding Round

New Leaf Venture Partners, Atlas Venture and Brace Pharma invested in a $65 million Series B venture round for Unum Therapeutics. The funding round was announced on 6/11/2015.

Transaction Overview

Company Name
Unum Therapeutics
Announced On
6/11/2015
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Investors

New Leaf Venture Partners (Lead Investor) (Liam Ratcliffe)

Atlas Venture (Bruce Booth)

Brace Pharma

Cowen Capital Partners

F-Prime Capital (Benjamin Auspitz)

Novo Ventures

Sabby Capital

Sanofi-Genzyme BioVentures

Wellington Management Company

Proceeds Purpose
The proceeds from the financing will be used to advance the Unum's novel Antibody-Coupled T-cell Receptor (ACTR) technology platform and support the expansion of the company's proprietary pipeline of ACTR therapies targeting a broad range of hematological and solid tumor targets.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Cambridge Park Dr. 3100
Cambridge, MA 02140
USA
Phone
(617) 945-5576
Website
www.unumrx.com
Email Address
[email protected]
Overview
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer.
Profile
Unum Therapeutics LinkedIn Company Profile
Social Media
Unum Therapeutics Company Twitter Account
Company News
Unum Therapeutics News
Facebook
Unum Therapeutics on Facebook
YouTube
Unum Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Chuck Wilson
  Chuck Wilson LinkedIn Profile  Chuck Wilson Twitter Account  Chuck Wilson News  Chuck Wilson on Facebook
Chief Financial Officer
John Green
  John Green LinkedIn Profile  John Green Twitter Account  John Green News  John Green on Facebook
Chief Medical Officer
Jessica Sachs
  Jessica Sachs LinkedIn Profile  Jessica Sachs Twitter Account  Jessica Sachs News  Jessica Sachs on Facebook
VP - Human Resources
Erin Schellhammer
  Erin Schellhammer LinkedIn Profile  Erin Schellhammer Twitter Account  Erin Schellhammer News  Erin Schellhammer on Facebook
VP - Operations
Larry Weiner
  Larry Weiner LinkedIn Profile  Larry Weiner Twitter Account  Larry Weiner News  Larry Weiner on Facebook
VP - R & D
Gregory Motz
  Gregory Motz LinkedIn Profile  Gregory Motz Twitter Account  Gregory Motz News  Gregory Motz on Facebook
VP - Regulatory Affairs
Todd Kenney
  Todd Kenney LinkedIn Profile  Todd Kenney Twitter Account  Todd Kenney News  Todd Kenney on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/11/2015: Whittl venture capital transaction
Next: 6/11/2015: Ostara Nutrient Recovery Technologies venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.